The results of the combination therapies of GLP‐1RAs with SGLT2i, as well as those of the GLP‐1/GIP and GLP‐1/GCGR co‐agonists look increasingly promising, and it is to be expected that further development and use of these therapies will favourably change the scenario of weight and glucose control in T2D. Here, GIP is linked to type 2 diabetes mellitus.